In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

What is the main barrier to reach LDL target levels in patients with coronary artery disease?

Session Poster Session 2

Speaker Andrea Velez Salas

Congress : EuroPrevent 2019

  • Topic : preventive cardiology
  • Sub-topic : Secondary Prevention
  • Session type : Poster Session
  • FP Number : P535

Authors : A Velez Salas (Madrid,ES), LA Martinez Marin (Madrid,ES), R Dalmau Gonzalez-Gallarza (Madrid,ES), A Rivas Perez (Madrid,ES), JM Garcia De Veas Marquez (Madrid,ES), L Rodriguez Sotelo (Madrid,ES), FJ Irazusta Cordoba (Madrid,ES), A Castro Conde (Madrid,ES), JL Lopez Sendon Herschel (Madrid,ES)

Authors:
A Velez Salas1 , LA Martinez Marin1 , R Dalmau Gonzalez-Gallarza1 , A Rivas Perez1 , JM Garcia De Veas Marquez1 , L Rodriguez Sotelo1 , FJ Irazusta Cordoba1 , A Castro Conde1 , JL Lopez Sendon Herschel1 , 1University Hospital La Paz - Madrid - Spain ,

Citation:

Introduction: statins are the cornerstone to reach LDL-cholesterol (LDL) goal in patients (pts) with coronary artery disease (CAD) recommended by the current guidelines (<70 mg/dl). This is not always achieved, mainly because of inadequate treatment adjustment during follow-up (therapeutic inertia), statin intolerance or poor adherence. The aim of this study is to analyse the causes of suboptimal achievement of LDL goals in pts with CAD. Methods: Retrospective study of pts with CAD included in a cardiac rehabilitation program (CRP) between September 2015 and April 2016. Baseline characteristics of the pts were analysed, as well as their lipid-lowering treatment, LDL levels and cardiovascular events during 18 months of follow up. Results: We analysed 200 pts, of which 37 were not on high dose statin at the end of the CRP. Among these, 17 pts had out-of-target levels during the follow up but only 5 (23.5%) received treatment adjustement and 3 of them had cardiovascular events at 18 months. Twenty-one pts reported statin-related symptoms (figure 1) that forced to lower or suspend the drug. LDL goal was only achieved in 6 of these pts (28.6%). In addition, 8 pts abandoned treatment for other reasons and all of them had poor LDL-C control. Ninety-one of the total of pts did not reach LDL target, and only 26.4% received ezetimibe or antiPCSK9. Conclusion: Therapeutic inertia and statin intolerance are important causes of failure in secondary prevention. Both are related, since pts that do not tolerate statins usually maintain the same treatment despite suboptimal LDL control. It is important to encourage the use of ezetimibe and antiPCSK9 to improve the achievement of LDL goals in secondary prevention.

Age (mean ±sd)

58.7 ±10.4

Sex (male)

166 (83%)

Hypertension

89 (44.5%)

Diabetes mellitus

47 (23.5%)

Dyslipidemia

119 (59.5%)

Smoker

99 (49.5%)

Overweight/obesity

161 (80.5%)

Atorvastatin 80 mg

162 (81%)

Rosuvastatin 20 mg

1 (0.5%)

Other statin

34 (17%)

Ezetimibe

39 (19.5%)

LDL-c target achievement

89 (44.5%)



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are